The market for antituberculosis drugs and vaccines: Incentives for investment in new products

Rochika G. Chaudhry, David M. Bishai

Research output: Contribution to journalReview articlepeer-review

Abstract

The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners.

Original languageEnglish (US)
Pages (from-to)775-781
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume5
Issue number6
DOIs
StatePublished - Dec 1 2005

Keywords

  • BCG
  • DOTS
  • Directly observed therapy short course
  • High-risk groups
  • Immunization
  • Market
  • TB
  • TB vaccine
  • Tuberculosis

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The market for antituberculosis drugs and vaccines: Incentives for investment in new products'. Together they form a unique fingerprint.

Cite this